(2)
The European Commission (EC) has approved single-dose, oral Xofluza for the treatment of uncomplicated influenza in patients aged 12 years and above
The EC has also approved Xofluza for post-exposure prophylaxis of influenza in individuals aged 12 years and above
Xofluza, with its rapid reduction in viral replication, could help patients recover more quickly, while also reducing the societal burden of influenza
Basel, 11 January 2021 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the European Commission (EC) has approved Xofluza (baloxavir marboxil) for the treatment of uncomplicated influenza in patients aged 12 years and above. In addition, the EC has approved Xofluza for post-exposure prophylaxis of influenza in individuals aged 12 years and above. Post-exposure prophylaxis aims to prevent influenza in individuals following contact with someone infected with the influenza virus. The Commission s Decision follows the positive opinion received from the European Me
The European Commission has approved single-dose, oral Xofluza for the treatment of uncomplicated influenza in patients aged 12 years and above The EC has also. | January 16, 2021
European Commission approves Roche s Phesgo (fixed-dose combination of Perjeta and Herceptin for subcutaneous injection) for people with HER2-positive breast cancer – IT Business Net itbusinessnet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from itbusinessnet.com Daily Mail and Mail on Sunday newspapers.
F. Hoffmann-La Roche Ltd: European Commission approves Roche s Phesgo (fixed-dose combination of Perjeta and Herceptin for subcutaneous injection) for people with HER2-positive breast cancer
1,2,3
administered under the skin in just minutes compared to hours with intravenous (
IV) infusion of Perjeta plus Herceptin
4,5,6
Approval is based on results from the pivotal phase III FeDeriCa trial, which showed that Phesgo delivered
non-inferior
7
Basel, 23 December 2020 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the European Commission has approved Phesgo
, a fixed-dose combination of Perjeta (pertuzumab) and Herceptin (trastuzumab) with hyaluronidase, administered by subcutaneous (SC; under the skin) injection for the treatment of early and metastatic HER2-positive breast cancer.
F. Hoffmann-La Roche Ltd
European Commission approves Roche’s Phesgo (fixed-dose combination of Perjeta and Herceptin for subcutaneous injection) for people with HER2-positive breast cancer
European Commission approves Roche’s Phesgo (fixed-dose combination of Perjeta and Herceptin for subcutaneous injection) for people with HER2-positive breast cancer
Subcutaneous administration is preferred by patients, physicians and healthcare providers, and is associated with a reduction in healthcare costs
1,2,3
administered under the skin in just minutes compared to hours with intravenous (
IV) infusion of Perjeta plus Herceptin
4,5,6
Approval is based on results from the pivotal phase III FeDeriCa trial, which showed that Phesgo delivered